Tumour Biomarkers: Homeostasis As a Novel Prognostic Indicator

Overview

Journal Open Biol

Specialties Biology
Cell Biology
Molecular Biology

Date 2016 Dec 9

PMID 27927793

Citations 9

Authors

Michela Falco

Giuseppe Palma

Domenica Rea

Davide De Biase

Stefania Scala

Massimiliano DAiuto

Gaetano Facchini

Sisto Perdona

Antonio Barbieri

Claudio Arra

Affiliations

Soon will be listed here.

Abstract

The term 'personalized medicine' refers to a medical procedure that consists in the grouping of patients based on their predicted individual response to therapy or risk of disease. In oncologic patients, a 'tailored' therapeutic approach may potentially improve their survival and well-being by not only reducing the tumour, but also enhancing therapeutic response and minimizing the adverse effects. Diagnostic tests are often used to select appropriate and optimal therapies that rely both on patient genome and other molecular/cellular analysis. Several studies have shown that lifestyle and environmental factors can influence the epigenome and that epigenetic events may be involved in carcinogenesis. Thus, in addition to traditional biomarkers, epigenetic factors are raising considerable interest, because they could potentially be used as an excellent tool for cancer diagnosis and prognosis. In this review, we summarize the role of conventional cancer genetic biomarkers and their association with epigenomics. Furthermore, we will focus on the so-called 'homeostatic biomarkers' that result from the physiological response to cancer, emphasizing the concept that an altered 'new' homeostasis influence not only tumour environment, but also the whole organism.

Citing Articles

Association between tumor markers elevation and poor functional outcomes after acute ischemic stroke: a longitudinal stroke center-based study.

Gu Y, Li Y, Gao L Ann Med. 2024; 56(1):2426753.

PMID: 39575674 PMC: 11587720. DOI: 10.1080/07853890.2024.2426753.

MicroRNAs' Crucial Role in Salivary Gland Cancers' Onset and Prognosis.

Bocchetti M, Grisolia P, Melisi F, Ferraro M, De Luca P, Camaioni A Cancers (Basel). 2022; 14(21).

PMID: 36358723 PMC: 9657964. DOI: 10.3390/cancers14215304.

Electrolyte Disorders Induced by Antineoplastic Drugs.

Verzicco I, Regolisti G, Quaini F, Bocchi P, Brusasco I, Ferrari M Front Oncol. 2020; 10:779.

PMID: 32509580 PMC: 7248368. DOI: 10.3389/fonc.2020.00779.

Determination of urokinase-type plasminogen activator serum levels in healthy and oncologic cats.

Viegas C, de Matos A, Leite-Martins L, Viegas I, Ferreira R, Gregorio H Can J Vet Res. 2020; 84(1):60-66.

PMID: 31949329 PMC: 6923816.

Decreased DC-SIGNR expression in hepatocellular carcinoma predicts poor patient prognosis.

Xia H, Wang H, Song S, Zhang J, He X, Hu Z Oncol Lett. 2020; 19(1):69-76.

PMID: 31897116 PMC: 6923947. DOI: 10.3892/ol.2019.11074.

References

Montuenga L, Pio R . Current challenges in lung cancer early detection biomarkers. Eur J Cancer. 2009; 45 Suppl 1:377-8. DOI: 10.1016/S0959-8049(09)70055-3. View

Grady W, Pritchard C . Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol. 2013; 42(1):124-39. PMC: 3947043. DOI: 10.1177/0192623313505155. View

French A, Sargent D, Burgart L, Foster N, Kabat B, Goldberg R . Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 2008; 14(11):3408-15. PMC: 2674786. DOI: 10.1158/1078-0432.CCR-07-1489. View

Negrini M, Calin G . Breast cancer metastasis: a microRNA story. Breast Cancer Res. 2008; 10(2):203. PMC: 2397516. DOI: 10.1186/bcr1867. View

Bickers B, Aukim-Hastie C . New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era. Anticancer Res. 2009; 29(8):3289-98. View

Rauch T, Zhong X, Wu X, Wang M, Kernstine K, Wang Z . High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci U S A. 2007; 105(1):252-7. PMC: 2224196. DOI: 10.1073/pnas.0710735105. View

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

Wang Z, Wang N, Chen J, Shen J . Emerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy. Evid Based Complement Alternat Med. 2012; 2012:873175. PMC: 3403522. DOI: 10.1155/2012/873175. View

Easton D, Ford D, Bishop D . Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995; 56(1):265-71. PMC: 1801337. View

10.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P . Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26(35):5705-12. DOI: 10.1200/JCO.2008.18.0786. View

11.

Jeronimo C, Usadel H, Henrique R, Silva C, Oliveira J, Lopes C . Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology. 2002; 60(6):1131-5. DOI: 10.1016/s0090-4295(02)01949-0. View

12.

Ross K, Carter H, Pearson J, Guess H . Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA. 2000; 284(11):1399-405. DOI: 10.1001/jama.284.11.1399. View

13.

Karpinets T, Foy B . Tumorigenesis: the adaptation of mammalian cells to sustained stress environment by epigenetic alterations and succeeding matched mutations. Carcinogenesis. 2005; 26(8):1323-34. DOI: 10.1093/carcin/bgi079. View

14.

Xinarianos G, McRonald F, Risk J, Bowers N, Nikolaidis G, Field J . Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small cell lung cancer. Hum Mol Genet. 2006; 15(13):2038-44. DOI: 10.1093/hmg/ddl128. View

15.

Tol J, Nagtegaal I, Punt C . BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009; 361(1):98-9. DOI: 10.1056/NEJMc0904160. View

16.

Catalona W, Partin A, Slawin K, Brawer M, Flanigan R, Patel A . Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279(19):1542-7. DOI: 10.1001/jama.279.19.1542. View

17.

Giacinti L, Claudio P, Lopez M, Giordano A . Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist. 2006; 11(1):1-8. DOI: 10.1634/theoncologist.11-1-1. View

18.

Palma G, De Laurenzi V, De Marco M, Barbieri A, Petrillo A, Caterina Turco M . Plasmacytoids dendritic cells are a therapeutic target in anticancer immunity. Biochim Biophys Acta. 2012; 1826(2):407-14. DOI: 10.1016/j.bbcan.2012.04.007. View

19.

Barbieri A, Bimonte S, Palma G, Luciano A, Rea D, Giudice A . The stress hormone norepinephrine increases migration of prostate cancer cells in vitro and in vivo. Int J Oncol. 2015; 47(2):527-34. DOI: 10.3892/ijo.2015.3038. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View